MedPath

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

Phase 2
Terminated
Conditions
Primary Fibromyalgia
Interventions
Registration Number
NCT01331109
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the long-term safety and efficacy of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • Patients must have completed or discontinued prematurely from lead-in study, MLN-MD-14, tolerating a minimum daily dose of 50mg milnacipran
Exclusion Criteria
  • Can not tolerate a minimum daily dose of 50mg milnacipran
  • Significant risk of suicidality
  • Pregnant or breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MilnacipranMilnacipranoral administration, twice daily dosing
Primary Outcome Measures
NameTimeMethod
Adverse EventsBaseline (Visit 1) to Week 53 (Visit 9)

Number of Patients who experience one or more treatment emergent adverse event (TEAE)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

Forest Investigative Site 042

🇺🇸

San Antonio, Texas, United States

Forest Investigative Site 063

🇺🇸

Seattle, Washington, United States

Forest Investigative Site 017

🇺🇸

Louisville, Kentucky, United States

Forest Investigative Site 045

🇺🇸

Fresno, California, United States

Forest Investigative Site 010

🇺🇸

Peoria, Illinois, United States

Forest Investigative Site 053

🇺🇸

Orange, California, United States

Forest Investigative Site 034

🇺🇸

Colorado Springs, Colorado, United States

Forest Investigative Site 012

🇺🇸

Fresno, California, United States

Forest Investigative Site 051

🇺🇸

Fresno, California, United States

Forest Investigative Site 033

🇺🇸

Bullhead City, Arizona, United States

Forest Investigative Site 024

🇺🇸

Rochester Hills, Michigan, United States

Forest Investigative Site 014

🇺🇸

Spring Hill, Florida, United States

Forest Investigative Site 050

🇺🇸

Sacramento, California, United States

Forest Investigative Site 025

🇺🇸

Clinton, Utah, United States

Forest Investigative Site 055

🇺🇸

West Palm Beach, Florida, United States

Forest Investigative Site 058

🇺🇸

Blue Ridge, Georgia, United States

Forest Investigative Site 016

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 015

🇺🇸

Dayton, Ohio, United States

Forest Investigative Site 009

🇺🇸

Ann Arbor, Michigan, United States

Forest Investigative Site 013

🇺🇸

Salt Lake City, Utah, United States

Forest Investigative Site 062

🇺🇸

Raleigh, North Carolina, United States

Forest Investigative Site 052

🇺🇸

Winston-Salem, North Carolina, United States

Forest Investigative Site 040

🇺🇸

Birmingham, Alabama, United States

Forest Investigative Site 035

🇺🇸

Orange, California, United States

Forest Investigative Site 003

🇺🇸

San Antonio, Texas, United States

Forest Investigative Site 004

🇺🇸

Racine, Wisconsin, United States

Forest Investigative Site 036

🇺🇸

Stevensville, Michigan, United States

Forest Investigative Site 049

🇺🇸

Whitehouse Station, New Jersey, United States

Forest Investigative Site 046

🇺🇸

Greer, South Carolina, United States

Forest Investigative Site 018

🇺🇸

Albuquerque, New Mexico, United States

Forest Investigative Site 023

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath